| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04487145 |
| P6099 | clinical trial phase | phase IV clinical trial | Q42825046 |
| P767 | contributor to the creative work or subject | Eunice Kennedy Shriver National Institute of Child Health and Human Development | Q5409765 |
| P17 | country | Uganda | Q1036 |
| P582 | end time | 2021-12-01 | |
| P921 | main subject | child | Q7569 |
| HIV | Q15787 | ||
| lopinavir | Q422585 | ||
| efavirenz | Q422645 | ||
| Drug-drug Interaction Ontology | Q55118364 | ||
| P4135 | maximum age | 17 | |
| P2899 | minimum age | 3 | |
| P1132 | number of participants | 190 | |
| P4844 | research intervention | dihydroartemisinin | Q5276420 |
| piperaquine | Q7197338 | ||
| P8005 | research subject recruitment status | not yet recruiting | Q76649614 |
| P1813 | short name | DPART | |
| P859 | sponsor | University of California, San Francisco | Q1061104 |
| P580 | start time | 2020-08-01 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | DPART Study: Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy |
Search more.